Overview
Status
Active
Registry date
2012-12-12
Share capital
5,000.00 PLN
Registered address
ul. Grzybowska 87, 00-844 Warszawa, Poland
Email
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 4 of 6 financial statements were filed late (the longest delay 974 days for 2019).
- 2025not filed
- 202404/07/2025
- 202304/07/2025
- 202216/06/2023
- 202116/06/2023
- 202016/06/2023
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Voivodeship · Mazowieckie110,855 / 142,035
Top 78%
Country · Poland395,926 / 495,867
Top 80%
Results vs industry
Revenue
This companyUSD 14.64kMedianUSD 55.66kAverageUSD 2.70m
Net profit
This companyUSD -1.62mMedianUSD -1.27kAverageUSD -92.16k
Operating costs
This companyUSD 1.54mMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 3.01mMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Grzegorz Andrzej Warzechaage 39 – President of the Management Board
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 50 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-08-23.
46 1020 1185 0000 4102 0357 2682
41 1020 1185 0000 4302 0357 2674
35 1020 1185 0000 4902 0371 7600
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Omnisepticasp. z o.o. | $3,475.29 | omniseptica.com | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com |
FAQ
The main business activity of Aperto focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on December 12, 2012.
The headquarters is located at: ul. Grzybowska 87, 00-844 Warszawa.
The management board consists of: Grzegorz Andrzej Warzecha (President of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $14,635 in 2024, which is an increase of 88.9% compared to 2023.
No, in 2024 the company was not profitable, reporting a net loss of $1,619,367. For comparison, in 2023 the loss was $336,906, meaning the company increased its loss by 356.5%.
The largest operating cost category falls under external services. This category amounted to $669,536 in 2024, representing 43% of all operating expenses.
Last updated: 2026-10-07